Volume 22 Issue 9
Sep.  2024
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2024  >  22(9): 1500-1503
LI Yang, LI Yumei, DENG Jun. Relationship between the changes of ER, PR, Her-2 and Ki-67 before and after neoadjuvant chemotherapy and chemotherapy efficacy in breast cancer[J]. Chinese Journal of General Practice, 2024, 22(9): 1500-1503. doi: 10.16766/j.cnki.issn.1674-4152.003668
Citation: LI Yang, LI Yumei, DENG Jun. Relationship between the changes of ER, PR, Her-2 and Ki-67 before and after neoadjuvant chemotherapy and chemotherapy efficacy in breast cancer[J]. Chinese Journal of General Practice, 2024, 22(9): 1500-1503. doi: 10.16766/j.cnki.issn.1674-4152.003668
shu

Relationship between the changes of ER, PR, Her-2 and Ki-67 before and after neoadjuvant chemotherapy and chemotherapy efficacy in breast cancer

doi: 10.16766/j.cnki.issn.1674-4152.003668

  • Department of Surgical Oncology, the First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui 233004, China

Funds:

 KJ2021A0703

  • Received Date: 2024-02-06
    Abstract
  •   Objective  To investigate the relationship between the changes of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2(Her-2) and proliferation-associated antigen (Ki-67) in breast cancer patients before and after neoadjuvant chemotherapy (NAC).  Methods  The data of 100 patients with breast cancer who received neoadjuvant chemotherapy in the First Affiliated Hospital of Bengbu Medical University from January 1, 2020 to December 31, 2021 were collected. Finally, 80 patients were included in the study. The NAC regimen used anthracycline combined with taxoid regimen, and the NAC regimen for Her-2 positive patients was docetaxel+carboplatin+trastuzumab+pertuzumab (TCbHP). After NAC, all patients underwent surgery for breast cancer. Immunohistochemical tests were performed on postoperative tumor residual samples, and the expression changes of related indicators were recorded. According to the grading of Miller-Payne system and postoperative pathological results, the patients were divided into pathologically complete response group (pCR) and non-pathologically complete response group (non-pCR). χ2 test and multiple logistic regression model were used to analyze the differences in the expression of ER, PR, Her-2 and Ki-67 before and after chemotherapy in the non-PCR group, and to analyze whether the expression changes of these molecules were correlated with the disease control rate of patients.  Results  The change rates of ER, PR, Her-2 and Ki-67 before and after NAC were 2.50%, 7.50%, 10.00% and 40.00%, respectively. There were statistically significant differences in the expression changes of Ki-67 (P=0.011) before and after NAC, while there were no statistically significant differences in the expression changes of ER (P=0.737), PR (P=0.581) and Her-2 (P=0.108). In addition, multiple logistic regression analysis showed that Ki-67 high expression was an independent predictor of clinical disease control rate of neoadjuvant chemotherapy (P < 0.05).  Conclusion  NAC treatment may affect Ki-67 expression, while ER, PR and Her-2 do not change significantly. Patients with reduced Ki-67 expression levels after NAC may have a higher rate of disease control.

     

    • FullText(HTML)
  • loading
    • References(18)
  • [1]
    NIKYAR N, TEGNELIUS E, VALACHIS A. Adjuvant locoregional radiation therapy in breast cancer patients with pathologic complete response after neoadjuvant chemotherapy: a systematic review and meta-analysis[J]. Clin Transl Radiat Oncol, 2022, 33: 45-52.
    [2]
    SHAABAN A M, PROVENZANO E. Receptor status after neoadjuvant therapy of breast cancer: significance and implications[J]. Pathobiology, 2022, 89(5): 297-308. doi: 10.1159/000521880
    [3]
    RAMTEKE P, SEENU V, PRASHAD R, et al. Alteration in steroid hormone and Her-2/neu receptor status following neoadjuvant chemotherapy in locally advanced breast cancer: experience at a tertiary care centre in India[J]. Indian J Cancer, 2016, 53(3): 366-371. doi: 10.4103/0019-509X.200669
    [4]
    TOLANEY S M, GOEL S, APPIAH A K, et al. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with HR+, HER2+ advanced breast cancer: plain language summary of the monarcHER study[J]. Future Oncol, 2023, 19(35): 2341-2348. doi: 10.2217/fon-2023-0078
    [5]
    BOUGHEY J C, HOSKIN T L, GOETZ M P. Neoadjuvant chemotherapy and nodal response rates in luminal breast cancer: effects of age and tumor Ki-67[J]. Ann Surg Oncol, 2022, 29(9): 5747-5756. doi: 10.1245/s10434-022-11871-z
    [6]
    SAJJADI E, VENETIS K, IVANOVA M, et al. Improving HER2 testing reproducibility in HER2-low breast cancer[J]. Cancer Drug Resist, 2022, 5(4): 882-888. doi: 10.20517/cdr.2022.29
    [7]
    王辉, 张慧芳, 周金强, 等. Ki-67、P53及CA153与乳腺癌腋窝淋巴结转移的相关性研究[J]. 中华全科医学, 2019, 17(9): 1518-1520.

    WANG H, ZHANG H F, ZHOU J Q, et al. Study on the correlation between Ki-67, P53 and CA153 and axillary lymph node metastasis of breast cancer[J]. Chinese Journal of General Practice, 2019, 17(9): 1518-1520.
    [8]
    ONISHI N, LI W, NEWITT D C, et al. Breast MRI during neoadjuvant chemotherapy: lack of background parenchymal enhancement suppression and inferior treatment response[J]. Radiology, 2021, 301(2): 295-308. doi: 10.1148/radiol.2021203645
    [9]
    BIDARD F C, KAKLAMANI V G, NEVEN P, et al. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase Ⅲ EMERALD Trial[J]. J Clin Oncol, 2022, 40(28): 3246-3256. doi: 10.1200/JCO.22.00338
    [10]
    TARANTINO P, MORGANTI S, CURIGLIANO G. Biologic therapy for advanced breast cancer: recent advances and future directions[J]. Expert Opin Biol Ther, 2020, 20(9): 1009-1024. doi: 10.1080/14712598.2020.1752176
    [11]
    SCHETTINI F, PRAT A. Dissecting the biological heterogeneity of HER2-positive breast cancer[J]. Breast, 2021, 59: 339-350. doi: 10.1016/j.breast.2021.07.019
    [12]
    HARBECK N, PENAULT-LLORCA F, CORTES J, et al. Breast cancer[J]. Nat Rev Dis Primers, 2019, 5(1): 66. doi: 10.1038/s41572-019-0111-2
    [13]
    JENSEN S G, THOMAS P E, CHRISTENSEN I J, et al. Evaluation of analytical accuracy of HER2 status in patients with breast cancer: comparison of HER2 GPA with HER2 IHC and HER2 FISH[J]. APMIS, 2020, 128(11): 573-582. doi: 10.1111/apm.13076
    [14]
    PATEL R, HOVSTADIUS M, KIER M W, et al. Correlation of the Ki-67 working group prognostic risk categories with the oncotype DX recurrence score in early breast cancer[J]. Cancer, 2022, 128(20): 3602-3609. doi: 10.1002/cncr.34426
    [15]
    KEPENEK F, KARAOǦLAN H, CAN C, et al. The role of basal metabolic and volumetric (18)F-FDG PET/CT parameters and their changes in predicting pathological complete response in breast cancer patients receiving neoadjuvant chemotherapy[J]. Hell J Nucl Med, 2022, 25(3): 235-246.
    [16]
    顾磊, 夏进东, 饶圣祥, 等. 乳腺癌磁共振表观扩散系数与Ki-67表达的相关性[J]. 中国临床医学, 2019, 26(6): 844-847.

    GU L, XIA J D, RAO S X, et al. Correlation between MRI apparent diffusion coefficient value and Ki-67 index in patients with breast cancer[J]. Chinese Journal of Clinical Medicine, 2019, 26(6): 844-847.
    [17]
    AKDENIZ N, KÖMEK H, KÜÇÜKÖNER M, et al. The role of basal 18F-FDG PET/CT maximum standard uptake value and maximum standard uptake change in predicting pathological response in breast cancer patients receiving neoadjuvant chemotherapy[J]. Nucl Med Commun, 2021, 42(3): 315-324. doi: 10.1097/MNM.0000000000001332
    [18]
    WONG S H, ZHAO L, ZHANG X, et al. Gavage of fecal samples from patients with colorectal cancer promotes intestinal carcinogenesis in germ-free and conventional mice[J]. Gastroenterology, 2017, 153(6): 1621-1633.e6. doi: 10.1053/j.gastro.2017.08.022
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(5)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (32) PDF downloads(3) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return